NSI-8226

Phase 2Biologic

UUniquity One (UNI)

NSI-8226 is one of 21 biologic programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Formoterol Fumarate

AstraZeneca

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

2 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

NSI-8226

UUniquity One (UNI)

Phase 2

1 9

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 10

Ozone

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Asthma

NCT06496607

Clinical

Trials by Indication[1]

Asthma1 trial

A Study to Evaluate Solriktug in Adult Participants With Asthma

Recruiting·UUniquity One (UNI)·Phase 2·NCT06496607·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NSI-8226. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NSI-8226 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NSI-8226. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Uniquity One (UNI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniquity One (UNI)

NSI-8226

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News